Sorengo, Switzerland

Marco Pizzutti

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Malnate, IT (2008 - 2012)
  • Sorengo, CH (2020 - 2021)

Company Filing History:


Years Active: 2008-2021

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Marco Pizzutti

Introduction

Marco Pizzutti, an accomplished inventor based in Sorengo, Switzerland, has made significant strides in the field of biochemistry with a focus on thyroid hormone solutions. With a total of four patents to his name, he has demonstrated a commitment to innovation and scientific advancement.

Latest Patents

Among his noteworthy inventions is the "High-stability packaged solutions of T4 thyroid hormone." This invention involves highly stable, alcohol-free, water-glycerol solutions of T4 thyroid hormone, specifically designed to minimize T3 impurity levels. The innovative aspect lies in the use of multi-barrier containers, which incorporate several layers of specialized materials to prevent contact between the solution and the external environment, enhancing stability and efficacy.

Career Highlights

Marco has contributed to several prominent companies, including Altergon SA and Ibsa Institut Biochemique S.A. His work in these organizations has been instrumental in advancing the understanding and application of thyroid hormone treatments.

Collaborations

Throughout his career, Marco has collaborated with notable professionals, including Giorgio Zoppetti and Nadia Puppini. Their collective expertise has fostered a dynamic environment conducive to research and innovation in hormonal therapies.

Conclusion

Marco Pizzutti's contributions to the field of biochemistry, particularly in developing stable T4 thyroid hormone solutions, underscore his role as a key innovator in the industry. His patents reflect a dedication to improving medical treatments and enhancing the quality of life for patients reliant on hormonal therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…